Abstract: Provided are an organic semiconductor material having a high charge mobility, oxidation stability, and solvent solubility, an organic semiconductor device using the same, and a novel aromatic heterocyclic compound to be used for the same and a production method therefor. The aromatic heterocyclic compound is represented by the following general formula (1), has two heteroatoms, and has a structure in which six rings are fused. In the formula, X represents an oxygen atom or N—R, and R represents hydrogen or a monovalent substituent. The organic semiconductor material contains the aromatic heterocyclic compound, and is used for an organic semiconductor film or an organic device, such as an organic thin-film transistor or an organic photovoltaic device.

Abstract: Provided are a semiconductor material for an organic transistor having a high charge mobility, solvent solubility, oxidation stability, and satisfactory film formability, and an organic thin-film transistor using the semiconductor material. The organic semiconductor material for an organic transistor is a seven-ring-fused heterocyclic compound having benzene rings at both ends, and having, therebetween, rings of a structure in which benzene rings A and pyrrole rings B are fused in the order of A-B-A-B-A. The fused heterocyclic compound may be substituted with an alkyl group, an alkenyl group, an alkynyl group, or an aromatic group. In addition, the organic thin-film transistor includes a semiconductor layer using the compound.

Abstract: Provided are an organic semiconductor material having a high charge mobility, oxidation stability, and solvent solubility, an organic semiconductor device using the same, and a novel aromatic heterocyclic compound to be used for the same and a production method therefor. The aromatic heterocyclic compound is represented by the following general formula (1), has two heteroatoms, and has a structure in which six rings are fused. In the formula, X represents an oxygen atom or N—R, and R represents hydrogen or a monovalent substituent. The organic semiconductor material contains the aromatic heterocyclic compound, and is used for an organic semiconductor film or an organic device, such as an organic thin-film transistor or an organic photovoltaic device.

Abstract: Provided are a semiconductor material for an organic transistor having a high charge mobility, solvent solubility, oxidation stability, and satisfactory film formability, and an organic thin-film transistor using the semiconductor material. The organic semiconductor material for an organic transistor is a seven-ring-fused heterocyclic compound having benzene rings at both ends, and having, therebetween, rings of a structure in which benzene rings A and pyrrole rings B are fused in the order of A-B-A-B-A. The fused heterocyclic compound may be substituted with an alkyl group, an alkenyl group, an alkynyl group, or an aromatic group. In addition, the organic thin-film transistor includes a semiconductor layer using the compound.

Abstract: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R1? is a hydrogen atom or lower alkyl which may be substituted; R2 is O, S, SO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W1, W2, and W3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.

Abstract: [Problem] To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders, metabolic disorders. [Means for Resolution] Provided are compound of a formula (I): [wherein R1 a and R1 b each are a hydrogen atom, etc.; R2 is a hydrogen atom, a C1-6 alkyl, etc.; Ar1 is a 6-membered aromatic carbocyclic group or a 6-membered aromatic nitrogen-containing heterocyclic group; Ar2 is a group to be formed by removing two hydrogen atoms from a 6-membered aromatic carbon ring, a 6-membered aromatic nitrogen-containing hetero ring, etc.; Ar3 is a mono- or bi-cyclic aromatic carbon ring or aromatic hetero ring; m1, m2, m3 and m4 each are independently 0, 1, 2, 3 or 4, provided that the total of m1 and m2 is from 2 to 6, the total of m3 and m4 is from 2 to 6]. The compounds are useful as medicines for central system disorders, cardiovascular disorders, metabolic disorders.

Abstract: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R1? is a hydrogen atom or lower alkyl which may be substituted; R2 is O, S, SO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W1, W2, and W3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.

Abstract: A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B1, B2, . . . , Bn?1 and Bn, (in which n is 4, 5 or 6) are each independently CH, N or the like; B?1, B?2, . . . , B?n?1 and B?n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.

Abstract: A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B1, B2, . . . , Bn?1 and Bn, (in which n is 4, 5 or 6) are each independently CH, N or the like; B?1, B?2, . . . , B?n?1 and B?n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.

Abstract: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R1? is a hydrogen atom or lower alkyl which may be substituted; R2 is O, S, SO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W1, W2, and W3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.

Abstract: A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B1, B2, . . . , Bn-1 and Bn, (in which n is 4, 5 or 6) are each independently CH, N or the like; B?1, B?2, . . . , B?n-1 and B?n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.